As shown in Fig. 3a and Table 1, mice fed with MCDD developed elevated intrahepatic steatosis (2.20 ± 0.63) and inflammation scores (2.00 ± 0.47), which could be lowered by recombinant SFRP5 treatment (1.40 ± 0.97 and 1.40 ± 0.70, respectively, both P < 0.05). Here, SFRP5 is linked to steatosis.